Healio10d
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
Healio13d
Oral TYK2 inhibitor has ‘outstanding efficiency’ in plaque psoriasis
A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque ...
Medscape5d
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
PMLive11d
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the data of the novel TYK2 inhibitor ...